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The incidence of hepatitis E in the UK is increas-
ing. We recommend measuring hepatitis E serol-
ogy in those with an acute hepatitis.
Case report
A 79 year-old Caucasian man presented to our
institution with jaundice and dark urine having
fallen from a ladder in his stables three days
prior to admission. The fall had left him with
some discomfort for which he had self-medicated
with paracetamol. He denied having exceeded the
recommended dose of paracetamol. There was no
past medical history of liver disease, illicit drug
use, drugs known to cause liver failure, or any
history of foreign travel. Physical examination
revealed icterus in the absence of clinical stigmata
of chronic liver disease.
Haematological and biochemical parameters
were consistent with acute hepatitis. The syn-
thetic function of the liver showed a rapidly wor-
sening trend with an initial albumin of 33 g/L
that worsened to 18 g/L and an initial INR of
1.4 that deteriorated to 2.5. Serology was negative
for hepatitis A, hepatitis B, hepatitis C, Epstein-
Barr virus and cytomegalovirus. HIV status was
not tested. Autoantibodies, alpha 1 antitrypsin,
immunoglobins, ferritin and copper were in the
normal range. Serum paracetamol was undetect-
able. An electrocardiogram did not show any
ischaemic features. An abdominal computed tom-
ography scan did not demonstrate any abnormal-
ity in the liver, with a patent hepatic vein and no
radiological evidence of portal hypertension or
cirrhosis.
Initially, the working diagnosis was paraceta-
mol induced subfulminant liver failure as a
result of therapeutic misadventure. Intravenous
N-acetyl cysteine therapy was commenced.
Despite these and general supportive measures
the patient continued to deteriorate with worsen-
ing liver function tests. Subsequently he became
encephalopathic and developed renal failure and
pneumonia and was considered too unstable for
consideration of an orthotopic liver transplant.
He failed to respond to further treatment and
died two weeks after presentation. Hepatitis E
virus (HEV) serology taken ante-mortem was
positive for anti-HEV IgM and anti-HEV IgG
thus suggesting a diagnosis of acute HEV infec-
tion. Apostmortem liver biopsy demonstrated his-
tological changes consistent with an acute
hepatitis with submassive necrosis.
Discussion
HEV is a small non-enveloped single stranded
RNA virus that causes an acute hepatitis similar
to hepatitis A.
1 The HEV has a single serotype,
with four genotypes having been identiﬁed.
HEV genotypes 1 and 2 exclusively infect
humans, whereas genotypes 3 and 4 infect
human and other animals, most notably swine.
Transmission is predominantly through the
faecal-oral route, most often through contami-
nation of water supplies and food and less com-
monly vertically or parenterally. Thus, HEV is
particularly prevalent in developing countries
where basic sanitation is poor. In such areas, mor-
tality from acute HEVis 0.5–3%, increasing to 20%
in pregnancy.
1 HEV is considered rare in the UK
and predominately occurs in travellers returning
from endemic areas. Mortality from acute HEV
in the UK is signiﬁcant at around 4%.
2 A recent
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1study from Italy examined 651 patients with acute
(non-A–C) hepatitis, and found that 20.6%
patients tested had acute HEV thus suggesting it
is not uncommon.
3
In the UK, 311 cases of acute HEV were
reported between 1993–2002 yet between 2003–
2008 a further 632 cases were reported.
2 These
data suggest a possible increase in the incidence
of HEV in the UK. However, this may only be a
pseudo-increase reﬂecting increasing awareness
of HEV among healthcare professionals.
4 The
increase in incidence of HEV is supported by
recent publications identifying cases in Birming-
ham,
5 Hereford,
2 and Devon and Cornwall.
6 It is
postulated that many of these cases were found
to have acquired HEV from the UK.
It has been proposed that the increase in preva-
lence in the UK is secondary to the consumption
of contaminated boar, pig, deer and venison
meat. In the UK, there have been reports of HEV
being associated with the consumption of
uncooked pork and shellﬁsh.
7 Studies have
demonstrated that 85% of UK pigs are
anti-HEV positive.
8,9 However, data are conﬂict-
ing with a recent study suggested that exposure
to pigs was not a signiﬁcant risk factor for acquir-
ing HEV.
10
It is interesting to note that the patient pre-
sented herein lived in a rural setting in Stafford-
shire. Although his water was supplied from the
mains, he did spend a considerable time pursuing
countryside activities. We hypothesize that these
may be the source of HEV acquisition. Of note is
that this case signiﬁcantly differs from previous
reports of UK acquired acute HEV infection in
that they were associated with a self-limiting
illness rather than acute fulminant liver failure
associated with mortality.
Drug-induced liver injury is relatively common
in the UK, accounting for 50% of all cases of acute
liver failure. A recent UK study has examined the
rates of HEV infection in subjects diagnosed with
drug-induced liver injury as it also presents with
a clinical picture similar to that of acute HEV
infection. Of 47 patients with a diagnosis of
drug-induced liver injury, six had serology
positive for HEV.
11 This study concludes that in
those patients in whom drug-induced liver
injury is suspected, HEV serology should be con-
comitantly tested with other standard serology
parameters.
HEV is usually a self-limiting illness and the
focus of management is excluding other causes
of acute hepatitis in association with supportive
treatment. Orthotopic liver transplantation for
acute fulminant liver failure secondary to HEV
has not, to the best of our knowledge, been sys-
tematically studied. However there are uncon-
trolled studies that suggest transplantation is a
treatment option in acute fulminant liver failure
secondary to HEV.
12 A recent study has evaluated
the safety and efﬁcacy of an HEV recombinant
protein vaccine in a phase 2, randomized, double-
blind, placebo-controlled trial and demonstrated a
small beneﬁt in those at high risk of developing
acute HEV infection.
13
Conclusion
This case demonstrates that acute UK
acquired HEV is an important, albeit rare, cause
of fulminant liver failure, which has a signiﬁcant
mortality. Thus, clinicians should routinely test
for HEV serology in patients with acute hepatitis.
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